Exploring Metabolomics and Other Biomarkers for Osteosarcopenic Adiposity Detection, Prevention and Management

Dear Colleagues,

Osteosarcopenic adiposity (OSA) syndrome, originally known as osteosarcopenic obesity (OSO), was identified in 2014. It is the most advanced stage on the spectrum of body composition disorders and includes simultaneous deterioration of bone (osteopenia/osteoporosis) and muscle (sarcopenia/dynapenia) with an increased presence of body fat (adipose tissue). Body fat may be manifested as an apparent overweight/obesity or as redistributed fat around organ tissues (visceral) and/or as infiltrated fat (ectopic) into bone, muscle and/or other organs. Since its conception, OSA has been studied across the world in diverse populations and with different methods/techniques and cutoff criteria used for its identification. However, there is no consensus on the methodology or diagnostic criteria, and many uncertainties still exist regarding its prevalence, management, and treatment. Therefore, the purpose of this Special Issue is to bring more insight into the metabolic nature of OSA by investigating the following:

1. Biomarkers for each tissue (bone, muscle, adipose) which, in combination, may indicate the existing impairments and presence of OSA, possibly discovering/identifying or proposing the series of omics.
2. In view of recent technological advances, such as genomic sequencing and molecular targeted drug exploitation, the concept of precision medicine can be used to demarcate OSA using multiple data sources from genomics to digital health metrics to artificial intelligence in order to facilitate an individualized yet “evidence-based” decisions regarding diagnostic and therapeutic approaches. In this way, therapeutics can be centered toward patients based on their molecular presentation rather than grouping them into broad categories with a “one size fits all” approach.
3. Any type of review or research article is welcome.

You may choose our Joint Special Issue in JPM.

Prof. Dr. Jasminka Ilich-Ernst
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• bone
• muscle
• adipose tissue
• osteosarcopenic adiposity
• nutrition, physical activity, and lifestyle habits influencing body composition